Diabetes
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Saltiel, A. R.
Right arrow Articles by Olefsky, J. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Saltiel, A. R.
Right arrow Articles by Olefsky, J. M.
Social Bookmarking
Add to CiteULike   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Diabetes, Vol 45, Issue 12 1661-1669, Copyright © 1996 by American Diabetes Association

ARTICLES

Thiazolidinediones in the treatment of insulin resistance and type II diabetes

AR Saltiel and JM Olefsky
Department of Signal Transduction, Parke-Davis Pharmaceutical Research Division, Warner Lambert, Ann Arbor, Michigan, USA.

Insulin resistance, characterized by reduced responsiveness to normal circulating concentrations of insulin, is a common feature of almost all patients with type II diabetes. The presumed central roles of both peripheral and hepatic insulin resistance suggest that the enhancement of insulin action might be an effective pharmacological approach to diabetes. Thiazolidinediones are a new class of orally active drugs that are designed to enhance the actions of insulin. These agents reduce insulin resistance by increasing insulin-dependent glucose disposal and reducing hepatic glucose output. Clinical studies in patients with type II diabetes, as well as other syndromes characterized by insulin resistance, have demonstrated that thiazolidinediones may represent a safe and effective new treatment. Although the precise mechanism of action of these drugs remains unknown, transcriptional changes are observed in tissue culture cells that produce enhanced insulin action. This regulation of gene expression appears to be mediated by the interactions of thiazolidinediones with a family of nuclear receptors known as the peroxisome proliferator-activated receptors (PPARs). The further elucidation of the molecular actions of these drugs may reveal much about the underlying mechanisms of insulin resistance.
Add to CiteULike CiteULike   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
 DiabetesHome page
F. Biscetti, E. Gaetani, A. Flex, T. Aprahamian, T. Hopkins, G. Straface, G. Pecorini, E. Stigliano, R. C. Smith, F. Angelini, et al.
Selective Activation of Peroxisome Proliferator-Activated Receptor (PPAR){alpha} and PPAR{gamma} Induces Neoangiogenesis Through a Vascular Endothelial Growth Factor-Dependent Mechanism
Diabetes, May 1, 2008; 57(5): 1394 - 1404.
[Abstract] [Full Text] [PDF]

Home page
 Arch NeurolHome page
J. Hardy and A. Singleton
The HapMap: Charting a Course for Genetic Discovery in Neurological Diseases
Arch Neurol, March 1, 2008; 65(3): 319 - 321.
[Abstract] [Full Text] [PDF]

Home page
 Toxicol SciHome page
C. R. Waites, M. A. Dominick, T. P. Sanderson, and B. E. Schilling
Nonclinical Safety Evaluation of Muraglitazar, a Novel PPAR{alpha}/{gamma} Agonist
Toxicol. Sci., November 1, 2007; 100(1): 248 - 258.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
Y. Fu, L. Luo, N. Luo, X. Zhu, and W. T. Garvey
NR4A Orphan Nuclear Receptors Modulate Insulin Action and the Glucose Transport System: POTENTIAL ROLE IN INSULIN RESISTANCE
J. Biol. Chem., October 26, 2007; 282(43): 31525 - 31533.
[Abstract] [Full Text] [PDF]

Home page
 Therapeutic Advances in Cardiovascular DiseaseHome page
C. Schindler
Review: The metabolic syndrome as an endocrine disease: is there an effective pharmacotherapeutic strategy optimally targeting the pathogenesis?
Therapeutic Advances in Cardiovascular Disease, October 1, 2007; 1(1): 7 - 26.
[Abstract] [PDF]

Home page
 Eur J EndocrinolHome page
S.-K. Kim, K.-Y. Hur, H.-J. Kim, W.-S. Shim, C.-W. Ahn, S.-W. Park, Y.-W. Cho, S.-K. Lim, H.-C. Lee, and B.-S. Cha
The increase in abdominal subcutaneous fat depot is an independent factor to determine the glycemic control after rosiglitazone treatment
Eur. J. Endocrinol., August 1, 2007; 157(2): 167 - 174.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
E. Wajcberg, A. Sriwijitkamol, N. Musi, R. A. DeFronzo, and E. Cersosimo
Relationship between Vascular Reactivity and Lipids in Mexican-Americans with Type 2 Diabetes Treated with Pioglitazone
J. Clin. Endocrinol. Metab., April 1, 2007; 92(4): 1256 - 1262.
[Abstract] [Full Text] [PDF]

Home page
 J. Physiol.Home page
E. R. Ropelle, J. R. Pauli, P. O. Prada, C. T. de Souza, P. K. Picardi, M. C. Faria, D. E. Cintra, M. F. d. A. Fernandes, M. B. Flores, L. A. Velloso, et al.
Reversal of diet-induced insulin resistance with a single bout of exercise in the rat: the role of PTP1B and IRS-1 serine phosphorylation
J. Physiol., December 15, 2006; 577(3): 997 - 1007.
[Abstract] [Full Text] [PDF]

Home page
 The Diabetes EducatorHome page
T. L. Skaer, D. A. Sclar, and L. M. Robison
Trends in the Prescribing of Oral Agents for the Management of Type 2 Diabetes Mellitus in the United States, 1990-2001: Does Type of Insurance Influence Access to Innovation?
The Diabetes Educator, November 1, 2006; 32(6): 940 - 953.
[Abstract] [Full Text] [PDF]

Home page
 DiabetesHome page
A. Yao-Borengasser, N. Rasouli, V. Varma, L. M. Miles, B. Phanavanh, T. N. Starks, J. Phan, H. J. Spencer III, R. E. McGehee Jr., K. Reue, et al.
Lipin Expression Is Attenuated in Adipose Tissue of Insulin-Resistant Human Subjects and Increases With Peroxisome Proliferator-Activated Receptor {gamma} Activation.
Diabetes, October 1, 2006; 55(10): 2811 - 2818.
[Abstract] [Full Text] [PDF]

Home page
 EndocrinologyHome page
X. Wang, Z. Hu, J. Hu, J. Du, and W. E. Mitch
Insulin Resistance Accelerates Muscle Protein Degradation: Activation of the Ubiquitin-Proteasome Pathway by Defects in Muscle Cell Signaling
Endocrinology, September 1, 2006; 147(9): 4160 - 4168.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Cell Physiol.Home page
D.-H. Cho, Y. J. Choi, S. A. Jo, J. Ryou, J. Y. Kim, J. Chung, and I. Jo
Troglitazone acutely inhibits protein synthesis in endothelial cells via a novel mechanism involving protein phosphatase 2A-dependent p70 S6 kinase inhibition
Am J Physiol Cell Physiol, August 1, 2006; 291(2): C317 - C326.
[Abstract] [Full Text] [PDF]

Home page
 Endocr Relat CancerHome page
J-R Weng, C-Y Chen, J J Pinzone, M D Ringel, and C-S Chen
Beyond peroxisome proliferator-activated receptor {gamma} signaling: the multi-facets of the antitumor effect of thiazolidinediones.
Endocr. Relat. Cancer, June 1, 2006; 13(2): 401 - 413.
[Abstract] [Full Text] [PDF]

Home page
 DiabetesHome page
P. D. van Poelje, S. C. Potter, V. C. Chandramouli, B. R. Landau, Q. Dang, and M. D. Erion
Inhibition of Fructose 1,6-Bisphosphatase Reduces Excessive Endogenous Glucose Production and Attenuates Hyperglycemia in Zucker Diabetic Fatty Rats
Diabetes, June 1, 2006; 55(6): 1747 - 1754.
[Abstract] [Full Text] [PDF]

Home page
 Hum ReprodHome page
K. Rautio, J.S. Tapanainen, A. Ruokonen, and L.C. Morin-Papunen
Endocrine and metabolic effects of rosiglitazone in overweight women with PCOS: a randomized placebo-controlled study
Hum. Reprod., June 1, 2006; 21(6): 1400 - 1407.
[Abstract] [Full Text] [PDF]

Home page
 J. Am. Soc. Nephrol.Home page
A. Benigni, C. Zoja, S. Tomasoni, M. Campana, D. Corna, C. Zanchi, E. Gagliardini, E. Garofano, D. Rottoli, T. Ito, et al.
Transcriptional Regulation of Nephrin Gene by Peroxisome Proliferator-Activated Receptor-{gamma} Agonist: Molecular Mechanism of the Antiproteinuric Effect of Pioglitazone
J. Am. Soc. Nephrol., June 1, 2006; 17(6): 1624 - 1632.
[Abstract] [Full Text] [PDF]

Home page
 Physiol. Rev.Home page
B. Desvergne, L. Michalik, and W. Wahli
Transcriptional Regulation of Metabolism
Physiol Rev, April 1, 2006; 86(2): 465 - 514.
[Abstract] [Full Text] [PDF]

Home page
 DiabetesHome page
A. B. Goldfine, S. Crunkhorn, M. Costello, H. Gami, E. J. Landaker, M. Niinobe, K. Yoshikawa, D. Lo, A. Warren, J. Jimenez-Chillaron, et al.
Necdin and E2F4 Are Modulated by Rosiglitazone Therapy in Diabetic Human Adipose and Muscle Tissue
Diabetes, March 1, 2006; 55(3): 640 - 650.
[Abstract] [Full Text] [PDF]

Home page
 DiabetesHome page
S. Franckhauser, S. Munoz, I. Elias, T. Ferre, and F. Bosch
Adipose Overexpression of Phosphoenolpyruvate Carboxykinase Leads to High Susceptibility to Diet-Induced Insulin Resistance and Obesity
Diabetes, February 1, 2006; 55(2): 273 - 280.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Endocrinol. Metab.Home page
S. J. Lessard, Z.-P. Chen, M. J. Watt, M. Hashem, J. J. Reid, M. A. Febbraio, B. E. Kemp, and J. A. Hawley
Chronic rosiglitazone treatment restores AMPK{alpha}2 activity in insulin-resistant rat skeletal muscle
Am J Physiol Endocrinol Metab, February 1, 2006; 290(2): E251 - E257.
[Abstract] [Full Text] [PDF]

Home page
 Arterioscler. Thromb. Vasc. Bio.Home page
F. Blaschke, Y. Takata, E. Caglayan, R. E. Law, and W. A. Hsueh
Obesity, Peroxisome Proliferator-Activated Receptor, and Atherosclerosis in Type 2 Diabetes
Arterioscler. Thromb. Vasc. Biol., January 1, 2006; 26(1): 28 - 40.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
A. P. M. Viljanen, K. A. Virtanen, M. J. Jarvisalo, K. Hallsten, R. Parkkola, T. Ronnemaa, F. Lonnqvist, P. Iozzo, E. Ferrannini, and P. Nuutila
Rosiglitazone Treatment Increases Subcutaneous Adipose Tissue Glucose Uptake in Parallel with Perfusion in Patients with Type 2 Diabetes: A Double-Blind, Randomized Study with Metformin
J. Clin. Endocrinol. Metab., December 1, 2005; 90(12): 6523 - 6528.
[Abstract] [Full Text] [PDF]

Home page
 J Clin PharmacolHome page
M. L. Christensen, B. Meibohm, E. V. Capparelli, P. Velasquez-Mieyer, G. A. Burghen, and W. V. Tamborlane
Single- and Multiple-Dose Pharmacokinetics of Pioglitazone in Adolescents With Type 2 Diabetes
J. Clin. Pharmacol., October 1, 2005; 45(10): 1137 - 1144.
[Abstract] [Full Text] [PDF]

Home page
 DiabetesHome page
J. K. Kim, H.-J. Kim, S.-Y. Park, A. Cederberg, R. Westergren, D. Nilsson, T. Higashimori, Y.-R. Cho, Z.-X. Liu, J. Dong, et al.
Adipocyte-Specific Overexpression of FOXC2 Prevents Diet-Induced Increases in Intramuscular Fatty Acyl CoA and Insulin Resistance
Diabetes, June 1, 2005; 54(6): 1657 - 1663.
[Abstract] [Full Text] [PDF]

Home page
 Diabetes CareHome page
J. P.H. van Wijk, E. J.P. de Koning, M. Castro Cabezas, and T. J. Rabelink
Rosiglitazone Improves Postprandial Triglyceride and Free Fatty Acid Metabolism in Type 2 Diabetes
Diabetes Care, April 1, 2005; 28(4): 844 - 849.
[Abstract] [Full Text] [PDF]

Home page
 DiabetesHome page
D. K. Kramer, L. Al-Khalili, S. Perrini, J. Skogsberg, P. Wretenberg, K. Kannisto, H. Wallberg-Henriksson, E. Ehrenborg, J. R. Zierath, and A. Krook
Direct Activation of Glucose Transport in Primary Human Myotubes After Activation of Peroxisome Proliferator-Activated Receptor {delta}
Diabetes, April 1, 2005; 54(4): 1157 - 1163.
[Abstract] [Full Text] [PDF]

Home page
 Exp. Biol. Med.Home page
C. L. Winter, J. S. Lange, M. G. Davis, G. S. Gerwe, T. R. Downs, K. G. Peters, and B. Kasibhatla
A Nonspecific Phosphotyrosine Phosphatase Inhibitor, Bis(maltolato)oxovanadium(IV), Improves Glucose Tolerance and Prevents Diabetes in Zucker Diabetic Fatty Rats
Experimental Biology and Medicine, March 1, 2005; 230(3): 207 - 216.
[Abstract] [Full Text] [PDF]

Home page
 DiabetesHome page
G. Boden, C. Homko, M. Mozzoli, L. C. Showe, C. Nichols, and P. Cheung
Thiazolidinediones Upregulate Fatty Acid Uptake and Oxidation in Adipose Tissue of Diabetic Patients
Diabetes, March 1, 2005; 54(3): 880 - 885.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Heart Circ. Physiol.Home page
K. B. Atkins, C. A. Northcott, S. W. Watts, and F. C. Brosius
Effects of PPAR-{gamma} ligands on vascular smooth muscle marker expression in hypertensive and normal arteries
Am J Physiol Heart Circ Physiol, January 1, 2005; 288(1): H235 - H243.
[Abstract] [Full Text] [PDF]

Home page
 Endocr. Rev.Home page
C. Knouff and J. Auwerx
Peroxisome Proliferator-Activated Receptor-{gamma} Calls for Activation in Moderation: Lessons from Genetics and Pharmacology
Endocr. Rev., December 1, 2004; 25(6): 899 - 918.
[Abstract] [Full Text] [PDF]

Home page
 Diabetes CareHome page
D. Choi, S.-K. Kim, S.-H. Choi, Y.-G. Ko, C.-W. Ahn, Y. Jang, S.-K. Lim, H.-C. Lee, and B.-S. Cha
Preventative Effects of Rosiglitazone on Restenosis After Coronary Stent Implantation in Patients With Type 2 Diabetes
Diabetes Care, November 1, 2004; 27(11): 2654 - 2660.
[Abstract] [Full Text] [PDF]

Home page
 DiabetesHome page
J. Matsui, Y. Terauchi, N. Kubota, I. Takamoto, K. Eto, T. Yamashita, K. Komeda, T. Yamauchi, J. Kamon, S. Kita, et al.
Pioglitazone Reduces Islet Triglyceride Content and Restores Impaired Glucose-Stimulated Insulin Secretion in Heterozygous Peroxisome Proliferator-Activated Receptor-{gamma}-Deficient Mice on a High-Fat Diet
Diabetes, November 1, 2004; 53(11): 2844 - 2854.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Endocrinol.Home page
J. Rieusset, J. Seydoux, S. I. Anghel, P. Escher, L. Michalik, N. Soon Tan, D. Metzger, P. Chambon, W. Wahli, and B. Desvergne
Altered Growth in Male Peroxisome Proliferator-Activated Receptor {gamma} (PPAR{gamma}) Heterozygous Mice: Involvement of PPAR{gamma} in a Negative Feedback Regulation of Growth Hormone Action
Mol. Endocrinol., October 1, 2004; 18(10): 2363 - 2377.
[Abstract] [Full Text] [PDF]

Home page
 Diabetes CareHome page
S. M. Strowig, M. L. Aviles-Santa, and P. Raskin
Improved Glycemic Control Without Weight Gain Using Triple Therapy in Type 2 Diabetes
Diabetes Care, July 1, 2004; 27(7): 1577 - 1583.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
H. R. Kast-Woelbern, S. L. Dana, R. M. Cesario, L. Sun, L. Y. de Grandpre, M. E. Brooks, D. L. Osburn, A. Reifel-Miller, K. Klausing, and M. D. Leibowitz
Rosiglitazone Induction of Insig-1 in White Adipose Tissue Reveals a Novel Interplay of Peroxisome Proliferator-activated Receptor {gamma} and Sterol Regulatory Element-binding Protein in the Regulation of Adipogenesis
J. Biol. Chem., June 4, 2004; 279(23): 23908 - 23915.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
K. He, R. E. Talaat, W. F. Pool, M. D. Reily, J. E. Reed, A. J. Bridges, and T. F. Woolf
METABOLIC ACTIVATION OF TROGLITAZONE: IDENTIFICATION OF A REACTIVE METABOLITE AND MECHANISMS INVOLVED
Drug Metab. Dispos., June 1, 2004; 32(6): 639 - 646.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Endocrinol.Home page
B. Desvergne, L. Michalik, and W. Wahli
Be Fit or Be Sick: Peroxisome Proliferator-Activated Receptors Are Down the Road
Mol. Endocrinol., June 1, 2004; 18(6): 1321 - 1332.
[Abstract] [Full Text] [PDF]

Home page
 Arterioscler. Thromb. Vasc. Bio.Home page
J. P.H. van Wijk and T. J. Rabelink
PPAR-{gamma} Agonists: Shifting Attention from the Belly to the Heart?
Arterioscler. Thromb. Vasc. Biol., May 1, 2004; 24(5): 798 - 800.
[Full Text]

Home page
 Drug Metab. Dispos.Home page
K. He, R. E. Talaat, and T. F. Woolf
INCORPORATION OF AN OXYGEN FROM WATER INTO TROGLITAZONE QUINONE BY CYTOCHROME P450 AND MYELOPEROXIDASE
Drug Metab. Dispos., April 1, 2004; 32(4): 442 - 446.
[Abstract] [Full Text] [PDF]

Home page
 EndocrinologyHome page
Q. Guo, S. P. Sahoo, P.-R. Wang, D. P. Milot, M. C. Ippolito, M. S. Wu, J. Baffic, C. Biswas, M. Hernandez, M.-H. Lam, et al.
A Novel Peroxisome Proliferator-Activated Receptor {alpha}/{gamma} Dual Agonist Demonstrates Favorable Effects on Lipid Homeostasis
Endocrinology, April 1, 2004; 145(4): 1640 - 1648.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
H. Yokoyama, M. Emoto, S. Fujiwara, K. Motoyama, T. Morioka, M. Komatsu, H. Tahara, H. Koyama, T. Shoji, M. Inaba, et al.
Quantitative Insulin Sensitivity Check Index and the Reciprocal Index of Homeostasis Model Assessment Are Useful Indexes of Insulin Resistance in Type 2 Diabetic Patients with Wide Range of Fasting Plasma Glucose
J. Clin. Endocrinol. Metab., March 1, 2004; 89(3): 1481 - 1484.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
H. Bays, L. Mandarino, and R. A. DeFronzo
Role of the Adipocyte, Free Fatty Acids, and Ectopic Fat in Pathogenesis of Type 2 Diabetes Mellitus: Peroxisomal Proliferator-Activated Receptor Agonists Provide a Rational Therapeutic Approach
J. Clin. Endocrinol. Metab., February 1, 2004; 89(2): 463 - 478.
[Full Text] [PDF]

Home page
 Am. J. Physiol. Endocrinol. Metab.Home page
J. R. Colca, W. G. McDonald, D. J. Waldon, J. W. Leone, J. M. Lull, C. A. Bannow, E. T. Lund, and W. R. Mathews
Identification of a novel mitochondrial protein ("mitoNEET") cross-linked specifically by a thiazolidinedione photoprobe
Am J Physiol Endocrinol Metab, February 1, 2004; 286(2): E252 - E260.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
D.-H. Cho, Y. J. Choi, S. A. Jo, and I. Jo
Nitric Oxide Production and Regulation of Endothelial Nitric-oxide Synthase Phosphorylation by Prolonged Treatment with Troglitazone: EVIDENCE FOR INVOLVEMENT OF PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR (PPAR) {gamma}-DEPENDENT AND PPAR{gamma}-INDEPENDENT SIGNALING PATHWAYS
J. Biol. Chem., January 23, 2004; 279(4): 2499 - 2506.
[Abstract] [Full Text] [PDF]

Home page
 DiabetesHome page
B. Guo, D. Koya, M. Isono, T. Sugimoto, A. Kashiwagi, and M. Haneda
Peroxisome Proliferator-Activated Receptor-{gamma} Ligands Inhibit TGF-{beta}1-Induced Fibronectin Expression in Glomerular Mesangial Cells
Diabetes, January 1, 2004; 53(1): 200 - 208.
[Abstract] [Full Text] [PDF]

Home page
 EndocrinologyHome page
I. Munir, H.-W. Yen, D. H. Geller, D. Torbati, R. M. Bierden, S. R. Weitsman, S. K. Agarwal, and D. A. Magoffin
Insulin Augmentation of 17{alpha}-Hydroxylase Activity Is Mediated by Phosphatidyl Inositol 3-Kinase But Not Extracellular Signal-Regulated Kinase-1/2 in Human Ovarian Theca Cells
Endocrinology, January 1, 2004; 145(1): 175 - 183.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
P. G. McTernan, F. M. Fisher, G. Valsamakis, R. Chetty, A. Harte, C. L. McTernan, P. M. S. Clark, S. A. Smith, A. H. Barnett, and S. Kumar
Resistin and Type 2 Diabetes: Regulation of Resistin Expression by Insulin and Rosiglitazone and the Effects of Recombinant Resistin on Lipid and Glucose Metabolism in Human Differentiated Adipocytes
J. Clin. Endocrinol. Metab., December 1, 2003; 88(12): 6098 - 6106.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
H. Ruan, M. J. Zarnowski, S. W. Cushman, and H. F. Lodish
Standard Isolation of Primary Adipose Cells from Mouse Epididymal Fat Pads Induces Inflammatory Mediators and Down-regulates Adipocyte Genes
J. Biol. Chem., November 28, 2003; 278(48): 47585 - 47593.
[Abstract] [Full Text] [PDF]

Home page
 Arterioscler. Thromb. Vasc. Bio.Home page
J. P.H. van Wijk, E. J.P. de Koning, E. P. Martens, and T. J. Rabelink
Thiazolidinediones and Blood Lipids in Type 2 Diabetes
Arterioscler. Thromb. Vasc. Biol., October 1, 2003; 23(10): 1744 - 1749.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
N. Enomoto, Y. Takei, M. Hirose, A. Konno, T. Shibuya, S. Matsuyama, S. Suzuki, K. I. T. Kitamura, and N. Sato
Prevention of Ethanol-Induced Liver Injury in Rats by an Agonist of Peroxisome Proliferator-Activated Receptor-{gamma}, Pioglitazone
J. Pharmacol. Exp. Ther., September 1, 2003; 306(3): 846 - 854.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
C. B. Juhl, M. Hollingdal, N. Porksen, A. Prange, F. Lonnqvist, and O. Schmitz
Influence of Rosiglitazone Treatment on {beta}-Cell Function in Type 2 Diabetes: Evidence of an Increased Ability of Glucose to Entrain High-Frequency Insulin Pulsatility
J. Clin. Endocrinol. Metab., August 1, 2003; 88(8): 3794 - 3800.
[Abstract] [Full Text] [PDF]

Home page
 Diabetes CareHome page
H. Yokoyama, M. Emoto, S. Fujiwara, K. Motoyama, T. Morioka, M. Komatsu, H. Tahara, T. Shoji, Y. Okuno, and Y. Nishizawa
Quantitative Insulin Sensitivity Check Index and the Reciprocal Index of Homeostasis Model Assessment in Normal Range Weight and Moderately Obese Type 2 Diabetic Patients
Diabetes Care, August 1, 2003; 26(8): 2426 - 2432.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
Z. Gao, A. Zuberi, M. J. Quon, Z. Dong, and J. Ye
Aspirin Inhibits Serine Phosphorylation of Insulin Receptor Substrate 1 in Tumor Necrosis Factor-treated Cells through Targeting Multiple Serine Kinases
J. Biol. Chem., June 27, 2003; 278(27): 24944 - 24950.
[Abstract] [Full Text] [PDF]

Home page
 DiabetesHome page
J. K. Kim, J. J. Fillmore, O. Gavrilova, L. Chao, T. Higashimori, H. Choi, H.-J. Kim, C. Yu, Y. Chen, X. Qu, et al.
Differential Effects of Rosiglitazone on Skeletal Muscle and Liver Insulin Resistance in A-ZIP/F-1 Fatless Mice
Diabetes, June 1, 2003; 52(6): 1311 - 1318.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
M. D. Aleo, G. R. Lundeen, D. K. Blackwell, W. M. Smith, G. L. Coleman, S. W. Stadnicki, and W. M. Kluwe
Mechanism and Implications of Brown Adipose Tissue Proliferation in Rats and Monkeys Treated with the Thiazolidinedione Darglitazone, a Potent Peroxisome Proliferator-Activated Receptor-{gamma} Agonist
J. Pharmacol. Exp. Ther., June 1, 2003; 305(3): 1173 - 1182.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Endocrinol. Metab.Home page
K. T. Iida, Y. Kawakami, M. Suzuki, H. Shimano, H. Toyoshima, H. Sone, K. Shimada, Y. Iwama, Y. Watanabe, H. Mokuno, et al.
Effect of thiazolidinediones and metformin on LDL oxidation and aortic endothelium relaxation in diabetic GK rats
Am J Physiol Endocrinol Metab, June 1, 2003; 284(6): E1125 - E1130.
[Abstract] [Full Text] [PDF]